Symbols / TWST $43.11 -3.78%
TWST Chart
About
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Diagnostics & Research | Market Cap | 2.64B |
| Enterprise Value | 2.66B | Income | -76.58M | Sales | 391.56M |
| Book/sh | 7.44 | Cash/sh | 3.23 | Dividend Yield | — |
| Payout | 0.00% | Employees | 979 | IPO | — |
| P/E | — | Forward P/E | -22.87 | PEG | — |
| P/S | 6.75 | P/B | 5.79 | P/C | — |
| EV/EBITDA | -23.61 | EV/Sales | 6.80 | Quick Ratio | 3.08 |
| Current Ratio | 3.78 | Debt/Eq | 24.79 | LT Debt/Eq | — |
| EPS (ttm) | -1.27 | EPS next Y | -1.89 | EPS Growth | — |
| Revenue Growth | 16.90% | Earnings | 2026-05-04 | ROA | -13.49% |
| ROE | -16.79% | ROIC | — | Gross Margin | 51.62% |
| Oper. Margin | -31.73% | Profit Margin | -19.56% | Shs Outstand | 61.31M |
| Shs Float | 54.65M | Short Float | 26.75% | Short Ratio | 8.32 |
| Short Interest | — | 52W High | 57.88 | 52W Low | 23.30 |
| Beta | 2.29 | Avg Volume | 1.27M | Volume | 355.30K |
| Target Price | $49.89 | Recom | Buy | Prev Close | $44.80 |
| Price | $43.10 | Change | -3.78% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$49.89
Mean price target
2. Current target
$42.68
Latest analyst target
3. DCF / Fair value
$-13.87
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$42.68
Low
$36.00
High
$58.00
Mean
$49.89
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-03 | main | Evercore ISI Group | Outperform → Outperform | $52 |
| 2026-02-03 | main | Barclays | Overweight → Overweight | $50 |
| 2026-01-26 | main | Guggenheim | Buy → Buy | $50 |
| 2026-01-08 | main | TD Cowen | Buy → Buy | $43 |
| 2025-12-15 | main | Barclays | Overweight → Overweight | $39 |
| 2025-11-17 | main | Barclays | Overweight → Overweight | $37 |
| 2025-11-04 | init | Stephens & Co. | — → Overweight | $41 |
| 2025-10-07 | main | Evercore ISI Group | Outperform → Outperform | $42 |
| 2025-10-02 | main | Barclays | Overweight → Overweight | $40 |
| 2025-05-06 | main | Goldman Sachs | Buy → Buy | $48 |
| 2025-05-06 | reit | Guggenheim | Buy → Buy | $50 |
| 2025-05-06 | main | Baird | Outperform → Outperform | $44 |
| 2025-05-06 | main | JP Morgan | Underweight → Underweight | $33 |
| 2025-04-10 | main | Barclays | Overweight → Overweight | $45 |
| 2025-02-04 | main | Scotiabank | Sector Outperform → Sector Outperform | $62 |
| 2025-02-04 | main | JP Morgan | Underweight → Underweight | $40 |
| 2025-02-04 | main | Baird | Outperform → Outperform | $54 |
| 2024-12-13 | init | Wolfe Research | — → Outperform | $60 |
| 2024-11-26 | reit | TD Cowen | Buy → Buy | $58 |
| 2024-11-19 | main | Barclays | Overweight → Overweight | $52 |
- Robert Chess Sells 10,000 Shares of Twist Bioscience (NASDAQ:TWST) Stock - MarketBeat hu, 19 Mar 2026 21
- Twist Bioscience (TWST) director’s 10b5-1 option exercise and 10K share sale - Stock Titan hu, 19 Mar 2026 20
- Twist Bioscience director chess sells $470,000 in shares - Investing.com hu, 19 Mar 2026 20
- The Bear Case: How TWST Behaves During Market Shocks - Trefis Wed, 11 Mar 2026 07
- Twist Bioscience stock falls after insider sale (TWST:NASDAQ) - Seeking Alpha Fri, 20 Feb 2026 08
- Assessing Twist Bioscience (TWST) Valuation After Insider Sale And Recent Q1 FY26 Optimism - Yahoo Finance Wed, 25 Feb 2026 08
- Fidelity proposes sale of 10,000 TWST shares (TWST) under Form 144 - Stock Titan ue, 17 Mar 2026 18
- Twist Bioscience Corporation $TWST Stock Holdings Lifted by Rafferty Asset Management LLC - MarketBeat Wed, 04 Mar 2026 08
- Twist Bioscience Stock Down 6.1% in One Day, Now Is Not The Time To Buy The Stock - Trefis Wed, 11 Mar 2026 07
- Will Twist Bioscience (TWST) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance Mon, 26 Jan 2026 08
- TWST SEC Filings - Twist Bioscience 10-K, 10-Q, 8-K Forms - Stock Titan ue, 17 Mar 2026 04
- Twist Bioscience Corporation $TWST Shares Acquired by EdgePoint Investment Group Inc. - MarketBeat Sun, 15 Mar 2026 11
- First Light Asset Management LLC Increases Position in Twist Bioscience Corporation $TWST - MarketBeat Mon, 16 Mar 2026 10
- Emily Leproust Sells 2,423 Shares of Twist Bioscience (NASDAQ:TWST) Stock - MarketBeat ue, 10 Mar 2026 07
- Tax-related share sale by Twist Bioscience (TWST) accounting chief disclosed - Stock Titan ue, 10 Mar 2026 20
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 425 | 19731 | — | Sale at price 46.43 per share. | CHO DENNIS | Officer | — | 2026-03-06 00:00:00 | D |
| 1 | 935 | 43408 | — | Sale at price 46.43 per share. | GREEN PAULA | Officer | — | 2026-03-06 00:00:00 | D |
| 2 | 246 | 11421 | — | Sale at price 46.43 per share. | WERNER ROBERT F. | Officer | — | 2026-03-06 00:00:00 | D |
| 3 | 2423 | 112490 | — | Sale at price 46.43 per share. | LEPROUST EMILY M | Chief Executive Officer | — | 2026-03-06 00:00:00 | D |
| 4 | 844 | 39423 | — | Sale at price 46.71 per share. | CHO DENNIS | Officer | — | 2026-02-23 00:00:00 | D |
| 5 | 1465 | 68430 | — | Sale at price 46.71 per share. | GREEN PAULA | Officer | — | 2026-02-23 00:00:00 | D |
| 6 | 1693 | 79080 | — | Sale at price 46.71 per share. | WERNER ROBERT F. | Officer | — | 2026-02-23 00:00:00 | D |
| 7 | 2085 | 97390 | — | Sale at price 46.71 per share. | LAPONIS ADAM | Chief Financial Officer | — | 2026-02-23 00:00:00 | D |
| 8 | 4294 | 200572 | — | Sale at price 46.71 per share. | FINN PATRICK JOHN | President | — | 2026-02-23 00:00:00 | D |
| 9 | 7205 | 336544 | — | Sale at price 46.71 per share. | LEPROUST EMILY M | Chief Executive Officer | — | 2026-02-23 00:00:00 | D |
Financials
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 10.26M | 0.00 | -2.15M | 942.60K |
| TaxRateForCalcs | 0.21 | 0.00 | 0.21 | 0.05 |
| NormalizedEBITDA | -160.25M | -99.54M | -167.34M | -230.53M |
| TotalUnusualItems | 48.85M | -44.93M | -10.26M | 18.85M |
| TotalUnusualItemsExcludingGoodwill | 48.85M | -44.93M | -10.26M | 18.85M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -77.67M | -208.73M | -204.62M | -217.86M |
| ReconciledDepreciation | 24.85M | 31.43M | 29.31M | 16.51M |
| ReconciledCostOfRevenue | 185.57M | 179.62M | 155.38M | 119.33M |
| EBITDA | -111.41M | -144.47M | -177.59M | -211.68M |
| EBIT | -136.26M | -175.90M | -206.90M | -228.19M |
| NetInterestIncome | 11.36M | 15.34M | 14.37M | 2.98M |
| InterestExpense | 29.00K | 5.00K | 80.00K | 367.00K |
| InterestIncome | 11.36M | 15.34M | 14.37M | 3.06M |
| NormalizedIncome | -116.26M | -163.80M | -196.52M | -235.77M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -77.67M | -208.73M | -204.62M | -217.86M |
| TotalExpenses | 512.83M | 488.88M | 452.01M | 452.59M |
| TotalOperatingIncomeAsReported | -136.26M | -220.83M | -217.16M | -234.78M |
| DilutedAverageShares | 59.81M | 58.02M | 56.88M | 53.88M |
| BasicAverageShares | 59.81M | 58.02M | 56.88M | 53.88M |
| DilutedEPS | -1.30 | -3.60 | -3.60 | -4.04 |
| BasicEPS | -1.30 | -3.60 | -3.60 | -4.04 |
| DilutedNIAvailtoComStockholders | -77.67M | -208.73M | -204.62M | -217.86M |
| NetIncomeCommonStockholders | -77.67M | -208.73M | -204.62M | -217.86M |
| NetIncome | -77.67M | -208.73M | -204.62M | -217.86M |
| NetIncomeIncludingNoncontrollingInterests | -77.67M | -208.73M | -204.62M | -217.86M |
| NetIncomeContinuousOperations | -77.67M | -208.73M | -204.62M | -217.86M |
| TaxProvision | 719.00K | 560.00K | 1.15M | -10.41M |
| PretaxIncome | -76.95M | -208.17M | -203.47M | -228.27M |
| OtherIncomeExpense | 47.94M | -47.61M | -10.93M | 17.77M |
| OtherNonOperatingIncomeExpenses | -903.00K | -2.68M | -672.00K | -1.09M |
| SpecialIncomeCharges | 48.85M | -44.93M | -10.26M | 18.85M |
| GainOnSaleOfBusiness | 48.85M | 0.00 | 0.00 | 4.61M |
| ImpairmentOfCapitalAssets | 0.00 | 44.93M | 6.79M | 0.00 |
| RestructuringAndMergernAcquisition | 0.00 | 0.00 | 3.47M | -14.24M |
| NetNonOperatingInterestIncomeExpense | 11.36M | 15.34M | 14.37M | 2.98M |
| InterestExpenseNonOperating | 29.00K | 5.00K | 80.00K | 367.00K |
| InterestIncomeNonOperating | 11.36M | 15.34M | 14.37M | 3.06M |
| OperatingIncome | -136.26M | -175.90M | -206.90M | -249.02M |
| OperatingExpense | 327.26M | 309.25M | 296.63M | 333.26M |
| ResearchAndDevelopment | 80.28M | 90.85M | 106.89M | 120.31M |
| SellingGeneralAndAdministration | 246.98M | 218.40M | 189.74M | 212.95M |
| GrossProfit | 191.00M | 133.35M | 89.73M | 84.23M |
| CostOfRevenue | 185.57M | 179.62M | 155.38M | 119.33M |
| TotalRevenue | 376.57M | 312.97M | 245.11M | 203.56M |
| OperatingRevenue | 376.57M | 312.97M | 245.11M | 203.56M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 60.63M | 58.88M | 57.56M | 56.52M |
| ShareIssued | 60.63M | 58.88M | 57.56M | 56.52M |
| TotalDebt | 75.57M | 85.03M | 94.07M | 94.91M |
| TangibleBookValue | 377.34M | 372.40M | 483.14M | 643.84M |
| InvestedCapital | 472.96M | 472.69M | 623.43M | 789.38M |
| WorkingCapital | 241.56M | 275.77M | 350.93M | 505.82M |
| NetTangibleAssets | 377.34M | 372.40M | 483.14M | 643.84M |
| CapitalLeaseObligations | 75.57M | 85.03M | 94.07M | 94.91M |
| CommonStockEquity | 472.96M | 472.69M | 623.43M | 789.38M |
| TotalCapitalization | 472.96M | 472.69M | 623.43M | 789.38M |
| TotalEquityGrossMinorityInterest | 472.96M | 472.69M | 623.43M | 789.38M |
| StockholdersEquity | 472.96M | 472.69M | 623.43M | 789.38M |
| GainsLossesNotAffectingRetainedEarnings | -627.00K | -522.00K | -756.00K | -1.84M |
| OtherEquityAdjustments | -627.00K | -522.00K | -756.00K | -1.84M |
| RetainedEarnings | -1.32B | -1.24B | -1.03B | -828.42M |
| AdditionalPaidInCapital | 1.79B | 1.72B | 1.66B | 1.62B |
| CapitalStock | 0.00 | 0.00 | 0.00 | 0.00 |
| CommonStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 168.90M | 141.63M | 152.97M | 171.99M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 77.50M | 70.63M | 79.65M | 81.33M |
| OtherNonCurrentLiabilities | 747.00K | 407.00K | 475.00K | 60.00K |
| NonCurrentDeferredLiabilities | 15.00M | 0.00 | ||
| NonCurrentDeferredRevenue | 15.00M | 0.00 | ||
| LongTermDebtAndCapitalLeaseObligation | 61.75M | 70.22M | 79.17M | 81.27M |
| LongTermCapitalLeaseObligation | 61.75M | 70.22M | 79.17M | 81.27M |
| CurrentLiabilities | 91.41M | 71.01M | 73.32M | 90.66M |
| OtherCurrentLiabilities | 722.00K | 961.00K | 430.00K | 12.60M |
| CurrentDeferredLiabilities | 6.88M | 2.13M | 3.00M | 3.48M |
| CurrentDeferredRevenue | 6.88M | 2.13M | 3.00M | 3.48M |
| CurrentDebtAndCapitalLeaseObligation | 13.82M | 14.80M | 14.90M | 13.64M |
| CurrentCapitalLeaseObligation | 13.82M | 14.80M | 14.90M | 13.64M |
| CurrentDebt | 1.55M | |||
| OtherCurrentBorrowings | 1.55M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 31.29M | 33.65M | 25.82M | 27.02M |
| PayablesAndAccruedExpenses | 38.69M | 19.46M | 29.18M | 33.92M |
| CurrentAccruedExpenses | 23.05M | 15.10M | 10.75M | 10.17M |
| Payables | 15.64M | 4.36M | 18.43M | 23.75M |
| OtherPayable | 5.06M | |||
| TotalTaxPayable | 4.54M | 2.73M | 4.37M | 3.66M |
| AccountsPayable | 11.09M | 1.63M | 14.05M | 20.09M |
| TotalAssets | 641.86M | 614.32M | 776.40M | 961.38M |
| TotalNonCurrentAssets | 308.89M | 267.55M | 352.15M | 364.90M |
| OtherNonCurrentAssets | 7.28M | 4.38M | 8.49M | 4.96M |
| NonCurrentNoteReceivables | 0.00 | 3.02M | ||
| InvestmentsAndAdvances | 54.34M | 1.52M | ||
| InvestmentinFinancialAssets | 54.34M | 1.52M | ||
| AvailableForSaleSecurities | 54.34M | 1.52M | ||
| GoodwillAndOtherIntangibleAssets | 95.62M | 100.29M | 140.29M | 145.55M |
| OtherIntangibleAssets | 13.43M | 14.48M | 54.48M | 59.74M |
| Goodwill | 82.19M | 85.81M | 85.81M | 85.81M |
| NetPPE | 151.66M | 161.35M | 203.36M | 214.39M |
| AccumulatedDepreciation | -94.99M | -75.64M | -50.66M | -31.78M |
| GrossPPE | 246.65M | 236.99M | 254.02M | 246.17M |
| Leases | 58.28M | 57.45M | 57.27M | 14.37M |
| ConstructionInProgress | 20.12M | 4.69M | 8.53M | 87.72M |
| OtherProperties | 150.96M | 158.36M | 176.04M | 137.23M |
| MachineryFurnitureEquipment | 17.30M | 16.50M | 12.18M | 6.84M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 332.97M | 346.78M | 424.26M | 596.48M |
| OtherCurrentAssets | 15.20M | 11.40M | 11.72M | 11.91M |
| PrepaidAssets | 11.91M | 8.28M | ||
| Inventory | 28.31M | 24.08M | 32.06M | 39.31M |
| FinishedGoods | 5.85M | 4.62M | 3.93M | 7.65M |
| WorkInProcess | 2.27M | 2.15M | 1.11M | 2.87M |
| RawMaterials | 20.19M | 17.32M | 27.02M | 28.79M |
| Receivables | 57.02M | 34.90M | 44.06M | 40.29M |
| ReceivablesAdjustmentsAllowances | -234.00K | -337.00K | ||
| OtherReceivables | 4.82M | 2.34M | ||
| AccountsReceivable | 57.02M | 34.90M | 44.06M | 40.29M |
| AllowanceForDoubtfulAccountsReceivable | -600.00K | -700.00K | -200.00K | -200.00K |
| GrossAccountsReceivable | 57.62M | 35.60M | 44.26M | 40.49M |
| CashCashEquivalentsAndShortTermInvestments | 232.43M | 276.40M | 336.41M | 504.97M |
| OtherShortTermInvestments | 49.38M | 50.08M | 49.94M | 126.28M |
| CashAndCashEquivalents | 183.05M | 226.32M | 286.47M | 378.69M |
| CashEquivalents | 150.37M | 199.86M | 245.65M | |
| CashFinancial | 32.68M | 26.46M | 40.82M |
| Line Item | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 |
|---|---|---|---|---|
| FreeCashFlow | -75.63M | -69.17M | -170.25M | -226.24M |
| RepurchaseOfCapitalStock | -16.00K | -3.98M | -4.41M | -7.75M |
| RepaymentOfDebt | 0.00 | 0.00 | -1.56M | -3.33M |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 269.82M | 323.86M |
| CapitalExpenditure | -28.00M | -5.08M | -27.78M | -101.86M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 9.00K | 167.00K |
| IncomeTaxPaidSupplementalData | 683.00K | 344.00K | 420.00K | 246.00K |
| EndCashPosition | 185.43M | 229.13M | 289.28M | 380.26M |
| BeginningCashPosition | 229.13M | 289.28M | 380.26M | 467.36M |
| EffectOfExchangeRateChanges | 143.00K | 126.00K | -27.00K | -319.00K |
| ChangesInCash | -43.85M | -60.27M | -90.95M | -86.78M |
| FinancingCashFlow | 28.54M | 6.89M | 911.00K | 270.53M |
| CashFlowFromContinuingFinancingActivities | 28.54M | 6.89M | 911.00K | 270.53M |
| NetOtherFinancingCharges | 15.00M | |||
| ProceedsFromStockOptionExercised | 13.56M | 10.87M | 5.32M | 10.02M |
| NetCommonStockIssuance | -16.00K | -3.98M | -4.41M | 262.07M |
| CommonStockPayments | -16.00K | -3.98M | -4.41M | -7.75M |
| CommonStockIssuance | 0.00 | 0.00 | 269.82M | 323.86M |
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | -1.56M | -3.33M |
| NetLongTermDebtIssuance | 0.00 | 0.00 | -1.56M | -3.33M |
| LongTermDebtPayments | 0.00 | 0.00 | -1.56M | -3.33M |
| InvestingCashFlow | -24.76M | -3.07M | 50.61M | -232.93M |
| CashFlowFromContinuingInvestingActivities | -24.76M | -3.07M | 50.61M | -232.93M |
| NetOtherInvestingChanges | -5.75M | |||
| NetInvestmentPurchaseAndSale | 742.00K | 2.00M | 78.39M | -117.16M |
| SaleOfInvestment | 50.13M | 53.91M | 154.74M | 100.48M |
| PurchaseOfInvestment | -49.39M | -51.91M | -76.34M | -217.64M |
| NetBusinessPurchaseAndSale | 2.50M | 0.00 | 0.00 | -13.91M |
| SaleOfBusiness | 2.50M | 0.00 | 0.00 | |
| PurchaseOfBusiness | 0.00 | 0.00 | -13.91M | -483.00K |
| NetPPEPurchaseAndSale | -28.00M | -5.08M | -27.78M | -101.86M |
| PurchaseOfPPE | -28.00M | -5.08M | -27.78M | -101.86M |
| OperatingCashFlow | -47.63M | -64.09M | -142.47M | -124.39M |
| CashFlowFromContinuingOperatingActivities | -47.63M | -64.09M | -142.47M | -124.39M |
| ChangeInWorkingCapital | -12.61M | 15.41M | -1.01M | -5.36M |
| ChangeInOtherWorkingCapital | 4.85M | 7.39M | ||
| ChangeInOtherCurrentLiabilities | 6.61M | -2.32M | -108.00K | -7.42M |
| ChangeInOtherCurrentAssets | -1.57M | 431.00K | 1.38M | 7.27M |
| ChangeInPayablesAndAccruedExpense | 12.68M | 485.00K | -1.03M | 14.50M |
| ChangeInAccruedExpense | 3.35M | 12.29M | 1.48M | 7.12M |
| ChangeInPayable | 9.33M | -11.80M | -2.51M | 7.38M |
| ChangeInAccountPayable | 9.33M | -11.80M | -2.51M | 7.38M |
| ChangeInPrepaidAssets | -3.72M | 382.00K | -4.17M | -2.55M |
| ChangeInInventory | -4.23M | 7.99M | 7.24M | -7.54M |
| ChangeInReceivables | -22.38M | 8.44M | -4.32M | -9.62M |
| ChangesInAccountReceivables | -22.38M | 8.44M | -4.32M | -9.62M |
| OtherNonCashItems | 2.18M | 1.93M | -3.22M | 7.26M |
| StockBasedCompensation | 64.46M | 50.92M | 30.28M | 79.66M |
| ProvisionandWriteOffofAssets | -11.00K | 40.00K | ||
| AssetImpairmentCharge | 0.00 | 44.93M | 6.79M | 0.00 |
| AmortizationOfSecurities | 1.31M | 593.00K | ||
| DepreciationAmortizationDepletion | 24.85M | 31.43M | 29.31M | 16.51M |
| DepreciationAndAmortization | 24.85M | 31.43M | 29.31M | 16.51M |
| OperatingGainsLosses | -48.85M | -4.61M | -3.00K | |
| GainLossOnInvestmentSecurities | -5.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 2.00K | ||
| GainLossOnSaleOfBusiness | -48.85M | 0.00 | 0.00 | -4.61M |
| NetIncomeFromContinuingOperations | -77.67M | -208.73M | -204.62M | -217.86M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TWST
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|